The Bioprocessing industry in the United States is witnessing rapid transformation, and one of the biggest growth drivers is the increasing adoption of single-use bioreactors. These disposable bioprocessing systems are becoming essential for modern biologics manufacturing, vaccine development, cell therapy production, and personalized medicine.

The global single-use bioreactors market, valued at US$4.1 billion in 2023, stood at US$4.4 billion in 2024 and is projected to advance at a resilient CAGR of 15.4% from 2024 to 2029, culminating in a forecasted valuation of US$9.1 billion by the end of the period.

Why is the Market Growing So Fast?

The demand for single-use bioreactors is accelerating because pharmaceutical and biotechnology companies are shifting toward faster, more flexible, and cost-efficient manufacturing systems.

Traditional stainless-steel bioreactors require extensive cleaning, sterilization, and validation procedures. In contrast, single-use systems use disposable bags and components, significantly reducing downtime and contamination risks.

Key growth drivers include:

• Rising demand for biologics and biosimilars
• Expansion of cell and gene therapy manufacturing
• Increased vaccine production capacity
• Lower operational and infrastructure costs
• Faster batch changeovers
• Growing adoption by CDMOs and biotech startups

The increasing popularity of personalized medicine has also boosted the need for scalable and flexible production systems, making single-use technologies highly attractive.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750

Market Trends Reshaping the Industry

1. Strong Adoption in Biopharmaceutical Manufacturing

Biopharmaceutical companies are rapidly integrating single-use technologies into upstream processing operations. Disposable bioreactors are especially valuable for mammalian cell culture applications, where sterility and flexibility are critical.

2. Growth of Cell & Gene Therapy

The expansion of advanced therapies is creating enormous opportunities for single-use bioreactor manufacturers. Cell therapy production often requires smaller, highly controlled batches, making disposable systems an ideal fit.

3. Increasing CDMO Investments

Contract development and manufacturing organizations are investing heavily in modular facilities powered by single-use systems. These facilities can quickly adapt to different client projects without major infrastructure modifications.

4. Technology Advancements

Modern single-use bioreactors now feature:

• Improved automation
• Advanced sensors
• Better scalability
• Real-time monitoring
• Enhanced mixing efficiency

These innovations are improving production consistency and process reliability.

Which Segment Dominates the Market?

Among different applications, mammalian cell culture currently represents the largest and fastest-growing segment in the U.S. single-use bioreactors market.

This dominance is primarily linked to the growing production of:

• Monoclonal antibodies
• Vaccines
• Recombinant proteins
• Cell therapies

Additionally, stirred-tank single-use bioreactors continue to lead the market due to their scalability and compatibility with commercial biologics production.

Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750

Key Companies Operating in the U.S. Market

Several major biotechnology and life sciences companies are driving innovation in this sector, including:

• Thermo Fisher Scientific
• Sartorius AG
• Danaher Corporation
• Merck KGaA
• PBS Biotech
• Eppendorf

These companies are focusing on expanding manufacturing capacity, launching advanced disposable systems, and strengthening automation capabilities.

Future Outlook

The future of the U.S. single-use bioreactors market looks exceptionally strong. As biologics manufacturing becomes more decentralized and personalized, flexible bioprocessing technologies will continue gaining momentum.

The industry is expected to benefit from:

• Continued biologics demand
• Expansion of mRNA and cell therapies
• Faster FDA approvals for advanced therapeutics
• Increased biotech startup activity
• Rising investments in biomanufacturing infrastructure

With strong technological innovation and increasing pharmaceutical adoption, single-use bioreactors are expected to remain a core pillar of next-generation biomanufacturing in the U.S.

North America region holds the largest share of the single-use bioreactors market.

The global single-use bioreactors market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. North America was the largest segment in 2023 in the single-use bioreactors market. The US accounted for the largest share of the North America single-use bioreactors market in 2023. Factors such as a highly advanced market in research and development, an increasing focus on biopharmaceutical product development, patent expirations, and growing support from government bodies contribute to this country’s largest market share. For instance, the US’s National Institutes of Health (NIH) program-level funding was ~USD 47.2 billion in 2023 and ~USD 47.6 billion as of March 2024. Moreover, Europe accounted for the second-largest share of the global single-use bioreactors market. Increasing R&D investments for biologics, increasing approval of biosimilars, rising prevalence of chronic diseases, and government initiatives are some factors driving the growth of the European single-use bioreactors market. In 2023, around 12 mAbs received European marketing approval. This will likely increase the demand for biologics & aid the growth of single-use bioreactors in Europe.